via Wistar Institute
Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR).
These finding were published today in Nature.
The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises.
“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, M.B.B.S., Ph.D., assistant professor in the Vaccine & Immunotherapy Center and lead author of the effort to identify a new generation of antimicrobials named dual-acting immuno-antibiotics (DAIAs).
Existing antibiotics target essential bacterial functions, including nucleic acid and protein synthesis, building of the cell membrane, and metabolic pathways. However, bacteria can acquire drug resistance by mutating the bacterial target the antibiotic is directed against, inactivating the drugs or pumping them out.
“We reasoned that harnessing the immune system to simultaneously attack bacteria on two different fronts makes it hard for them to develop resistance,” said Dotiwala.
He and colleagues focused on a metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids — molecules required for cell survival in most pathogenic bacteria. The lab targeted the IspH enzyme, an essential enzyme in isoprenoid biosynthesis, as a way to block this pathway and kill the microbes. Given the broad presence of IspH in the bacterial world, this approach may target a wide range of bacteria.
Researchers used computer modeling to screen several million commercially available compounds for their ability to bind with the enzyme, and selected the most potent ones that inhibited IspH function as starting points for drug discovery.
Since previously available IspH inhibitors could not penetrate the bacterial cell wall, Dotiwala collaborated with Wistar’s medicinal chemist Joseph Salvino, Ph.D., professor in The Wistar Institute Cancer Center and a co-senior author on the study, to identify and synthesize novel IspH inhibitor molecules that were able to get inside the bacteria.
The team demonstrated that the IspH inhibitors stimulated the immune system with more potent bacterial killing activity and specificity than current best-in-class antibiotics when tested in vitro on clinical isolates of antibiotic-resistant bacteria, including a wide range of pathogenic gram negative and gram positive bacteria. In preclinical models of gram negative bacterial infection, the bactericidal effects of the IspH inhibitors outperformed traditional pan antibiotics. All compounds tested were shown to be nontoxic to human cells.
“Immune activation represents the second line of attack of the DAIA strategy,” said Kumar Singh, Ph.D., Dotiwala lab postdoctoral fellow and first author of the study.
“We believe this innovative DAIA strategy may represent a potential landmark in the world’s fight against AMR, creating a synergy between the direct killing ability of antibiotics and the natural power of the immune system,” echoed Dotiwala.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New class of antibiotics
- Anifera looks to new way to treat bovine mastitis, improve efficacy of antibioticson August 27, 2021 at 5:27 am
Animal health company, Anifera, has received further investment from Stonehaven Incubate to initiate additional studies of its adjunct therapy in relation to bovine mastitis.
- Law enforcement officials warn of counterfeit drugs as students head back to classon August 26, 2021 at 3:51 pm
WE ARE SEIZING THOSE PILLS ON A REGULAR BASIS THROUGHOUT THE FOUR CORNERS OF NEW HAMPSHIRE. SCOTT ... officials are warning schools about counterfeit drugs as students head back to class.The Drug ...
- Global Antibacterial Drugs Market to Surge to US$ 51 Bn by the End of the Year 2025on August 26, 2021 at 2:44 pm
The antibacterial drugs market is encountering numerous challenges, ranging from regulatory barriers, patent expirations, to low returns on investment. Patent expirations of blockbuster drugs are ...
- Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use ...on August 25, 2021 at 3:50 am
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Co ...
- Nanotechnology Is Adding a New Paradigm In the Development of Anti-Platelet Medications : Report Fact.MRon August 24, 2021 at 10:39 pm
According to a study published by Fact.MR, retail pharmacies are projected to witness a CAGR of 2.9% during 2020-2027.Nanotechnology is adding a new paradigm in the development of atherosclerosis ...
Go deeper with Google Headlines on:
New class of antibiotics
Go deeper with Bing News on:
Drug-resistant bacterial pathogens
- Oral bacteria of wild Swedish brown bears reveal history of human antibiotic useon August 26, 2021 at 5:00 pm
Antibiotic resistance is a major global health threat and hundreds of thousands of people die each year because of infections with resistant bacteria. Antibiotics and resistant bacteria, e.g., from ...
- BioPlx sets out to control and combat the rise of antibiotic-resistant superbugson August 25, 2021 at 10:17 pm
Antimicrobial Resistance is "one of the greatest threats to society, human and animal health, and economic prosperity." Those are the unequivocal words regarding the gravity of antimicrobial-resistant ...
- Antibiotic use in medicine, agriculture led to increasing resistance in animals, study findson August 25, 2021 at 9:22 am
Increased use of antibiotics in medicine and agriculture from the 1950s through the 1990s led to a rise in resistance to the drugs among wild Swedish brown bears, a study published Wednesday by ...
- Antibiotic resistance has spread to the deep, dark forest, bear teeth revealon August 25, 2021 at 8:05 am
DNA from the animals’ teeth now reveals that, almost immediately after antibiotics were introduced in the 1950s, the drugs had penetrated even the remotest Swedish forests. The new finding, out today, ...
- We can track antibiotic resistance in wild bears’ tooth plaqueon August 25, 2021 at 8:03 am
The mouth bacteria of wild bears in Sweden hold a historical record of human antibiotic use and the rise of antimicrobial resistance ...